A Clinical Study of Immune Globulin Subcutaneous (Human) (IGSC), 20% for the Evaluation of Efficacy, Safety, and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006622/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to develop a 20% subcutaneous immunoglobulin treatment option for
patients with primary immunodeficiency (PID) diseases.
提供机构：
Vivli
创建时间：
2021-01-27
